Triple Negative Breast Neoplasms: all 1,163 studies
Page 1 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.
- Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast CancerNot yet recruitingNCT07884721Not applicable
- Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant TreatmentNot yet recruitingNCT07884201Phase 2
- Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast CancerRecruitingNCT07880600
- A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07879911Phase 3
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)Not yet recruitingNCT07876557Phase 2
- TROPION Breast Respond in 1L TNBCNot yet recruitingNCT07867470
- US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and ChemotherapyNot yet recruitingNCT07862751Phase 2
- Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast CancerNot yet recruitingNCT07857486Phase 2
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingNCT07856225
- Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.Not yet recruitingNCT07847398Not applicable
- Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast CancerRecruitingNCT07844473Not applicable
- Senocohort: Identification of Predictive Biomarkers in Breast Cancer TreatmentNot yet recruitingNCT07833891
- Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)Not yet recruitingNCT07828652
- Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast CancerRecruitingNCT07808086
- A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsRecruitingNCT07801508Phase 1
- Sacituzumab Govitecan and Q901 in Advanced TNBCNot yet recruitingNCT07788222Phase 2
- Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBCNot yet recruitingNCT07786428Phase 2
- Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)RecruitingNCT07776951Not applicable
- A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast CancerRecruitingNCT07768436Phase 2
- Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingNCT07762703Phase 1/2
- An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBCNot yet recruitingNCT07760844Phase 3
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingNCT07752550Phase 2
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsRecruitingNCT07749586Phase 1/2
- A Study of IOV-5001 in Adults With Advanced Solid TumorsNot yet recruitingNCT07743723Phase 1/2
- Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBCNot yet recruitingNCT07743632Phase 2
- A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)RecruitingNCT07743190Phase 2
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast CancerRecruitingNCT07741968Not applicable
- Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingNCT07739485Phase 1/2
- Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory MalignanciesNot yet recruitingNCT07730125Phase 1/2
- A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)RecruitingNCT07729956Phase 3
- Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving SurgeryNot yet recruitingNCT07723469Phase 3
- A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer BurdenNot yet recruitingNCT07721259Phase 2
- Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBCRecruitingNCT07705438
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT07705334Phase 1
- Enhancing ICB Efficacy Through IL-1 Inhibition in TNBCNot yet recruitingNCT07698106Phase 1/2
- Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast CancerNot yet recruitingNCT07687446
- Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System DiseaseNot yet recruitingNCT07681297Phase 1/2
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerRecruitingNCT07679360Phase 3
- Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After ProgressionNot yet recruitingNCT07672431Not applicable
- Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCRecruitingNCT07671092Early Phase 1
- An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBCNot yet recruitingNCT07669610Phase 3
- Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast CancerNot yet recruitingNCT07662252
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerRecruitingNCT07652242Phase 1
- THE-0504 in Patients With Solid TumorsRecruitingNCT07646106Phase 1
- Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.RecruitingNCT07638852Phase 2
- Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsRecruitingNCT07630961Phase 1
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Phase 2
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT07623369Phase 1
- Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain MetastasesRecruitingNCT07619534
- Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER TrialNot yet recruitingNCT07610525Phase 2
- QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast CancerRecruitingNCT07601178Phase 2
- ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapyNot yet recruitingNCT07597642Not applicable
- Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)Not yet recruitingNCT07581314Phase 1/2
- Predicting Response to Immunochemotherapy in Early Triple Negative Breast CancerRecruitingNCT07570524
- A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07556848Phase 3
- Pilot Study of Bone Mineral Density Changes During Anti-PD-1 ImmunotherapyRecruitingNCT07555210Not applicable
- Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast CancerNot yet recruitingNCT07552181Phase 2
- Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.Not yet recruitingNCT07551765
- Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingNCT07551050
- Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC StudyRecruitingNCT07546695
- A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersRecruitingNCT07545122Phase 1
- A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerRecruitingNCT07544056Phase 2/3
- An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)AvailableNCT07536815
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareRecruitingNCT07533123Phase 3
- HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.Not yet recruitingNCT07528768Phase 2
- Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)Not yet recruitingNCT07527819
- An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant TherapyRecruitingNCT07525869Not applicable
- Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBCNot yet recruitingNCT07523789
- Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Phase 1/2
- Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsRecruitingNCT07517198Phase 1
- A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast CancerRecruitingNCT07513311Not applicable
- Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCRecruitingNCT07510802Phase 1/2
- QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.Not yet recruitingNCT07509515Phase 2
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesRecruitingNCT07503808Phase 1
- Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Not yet recruitingNCT07487519Phase 2
- Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNot yet recruitingNCT07486687Phase 3
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)RecruitingNCT07486089Phase 1/2
- Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and ImagingNot yet recruitingNCT07478705Not applicable
- Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingNCT07466303Phase 2
- Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast CancerNot yet recruitingNCT07458204Phase 2
- Sac-TMT for Active TNBC Brain MetastasesNot yet recruitingNCT07458113Phase 2
- Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast CancerRecruitingNCT07457359Phase 2
- A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA MutationNot yet recruitingNCT07441512Phase 2
- A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard TherapyNot yet recruitingNCT07423117Phase 1
- Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast CancerNot yet recruitingNCT07419880Phase 2
- Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT07413601Phase 2
- Adjuvant Intensification for LARNot yet recruitingNCT07407517Phase 3
- Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast CancerRecruitingNCT07401537Phase 2
- Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.RecruitingNCT07394387Phase 2
- FMD and Neoadjuvant Chemo-immunotherapy in TNBCRecruitingNCT07378306Phase 2
- Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapyNot yet recruitingNCT07357948Not applicable
- Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)RecruitingNCT07351487Phase 2
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast CancerRecruitingNCT07342283Phase 2
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
- Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesRecruitingNCT07340541Phase 2
- Intratumoral N17350 in Advanced Solid TumorsRecruitingNCT07339176Phase 1/2
- ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBCRecruitingNCT07332975
- Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)RecruitingNCT07327489
- MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBCRecruitingNCT07327021Phase 2
- A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast CanceRecruitingNCT07321015Phase 2